[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Heart Health Research Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645175","finerenone-and-empagliflozin-combination-in-obesity-with-hypertension-a-12-week-prospective-parallel-design-double-blind-randomized-placebo-controlled-trial-100645175",false,"NCT07678151","Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial","Inclusion Criteria:\n\nAge ≥ 40 years.\n\nBody mass index (BMI) ≥ 28 kg\u002Fm² or abdominal obesity, defined as meeting any of the following:\n\nWaist circumference ≥ 90 cm (male) or ≥ 85 cm (female); Waist-to-hip ratio ≥ 0.9 (male) or ≥ 0.85 (female); Waist-to-height ratio ≥ 0.5. Unattended office systolic blood pressure (SBP) ≥ 140 mmHg and \\\u003C 160 mmHg during the screening period (within 1 week before randomization).\n\nCurrently taking no more than 2 antihypertensive agents (fixed-dose combinations are counted by the number of active ingredients).\n\nNo changes in the type or dose of antihypertensive medications within 4 weeks before the screening visit.\n\nProvide written informed consent.\n\nExclusion Criteria:\n\nDiastolic blood pressure ≥ 100 mmHg. Diagnosed diabetes mellitus or fasting plasma glucose ≥ 7.0 mmol\u002FL. History of heart failure (any ejection fraction) or left ventricular ejection fraction \\\u003C 50%.\n\nAcute coronary syndrome, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) within 90 days.\n\nStroke or transient ischemic attack (TIA) within 90 days. Known secondary hypertension (e.g., bilateral renal artery stenosis \\>75%, aldosteronism, pheochromocytoma), except documented sleep apnea.\n\nSevere hepatic dysfunction (AST\u002FALT \\> 3× upper limit of normal, or Child-Pugh class C).\n\nAcute kidney injury within 6 months before screening, or eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m², or kidney transplant (or planned).\n\nPrimary adrenal insufficiency (Addison's disease). Contraindications to any component of the study drugs (e.g., urinary tract infection within 90 days, serum potassium \\> 5.0 mmol\u002FL, drug allergy).\n\nMajor surgery under general anesthesia within 90 days before screening, or elective surgery planned within 90 days after screening.\n\nGastrointestinal surgery or disease that, in the investigator's judgment, may affect absorption of the study drug.\n\nPregnancy, lactation, or planned pregnancy (for both male and female participants) during the study period.\n\nActive malignancy. Life expectancy \\\u003C 3 months. Use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampicin, carbamazepine, phenytoin) that cannot be discontinued within 7 days before Day 1.\n\nUse of mineralocorticoid receptor antagonists (e.g., finerenone, eplerenone, spironolactone), renin inhibitors, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), or SGLT-1\u002F2 inhibitors (e.g., canagliflozin) within 8 weeks before screening or during the intervention period.\n\nUse of potassium supplements, potassium-sparing diuretics (e.g., amiloride, triamterene), or potassium-binding agents within 8 weeks before screening or during the intervention period.\n\nParticipation in a clinical trial of empagliflozin or finerenone within 1 month before screening.\n\nCurrent use of weight-loss medications (e.g., GLP-1 receptor agonists, GIP\u002FGLP-1 dual agonists, GLP-1\u002FGCGR dual agonists) or prior\u002Fplanned bariatric surgery.\n\nKnown or suspected orthostatic hypotension or autonomic dysfunction. Any condition that, in the investigator's opinion, makes the participant unsuitable for the study.","ALL","40 Years",{"count":18,"type":19},260,"ESTIMATED","INTERVENTIONAL",[22],"NA","The EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg\u002Fday) with finerenone (10 mg\u002Fday, up-titrated to 20 mg after 4 weeks) can significantly lower office systolic blood pressure in adults with obesity and stage 1 hypertension (systolic BP 140-160 mmHg) who are on up to two stable antihypertensives. The study will enroll 260 participants from community settings. Beyond blood pressure, the trial will also assess effects on diastolic pressure, cumulative BP exposure, urinary albumin-to-creatinine ratio, inflammation (hs-CRP), fasting glucose, body weight, and quality of life. Safety monitoring focuses on hyperkalemia, acute kidney injury, hypotension, and hypoglycemia. If positive, this research may offer a new, mechanism-based therapeutic strategy for the growing population with cardiometabolic risk, potentially providing better cardiovascular and kidney protection than conventional approaches.",[25],"Hypertension (HTN)",[27,28,29,30],"Sodium-Glucose Transporter 2 Inhibitors","Mineralocorticoid Receptor Antagonists","Blood Pressure","Obesity","NOT_YET_RECRUITING","2026-06-25",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":19},"2026-07-13",{"date":39,"type":19},"2027-08-31",{"name":41,"class":42},"Heart Health Research Center","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100551114","mobile-applet-for-weight-management-in-obese-heart-failure-patients-100551114","NCT06455878","Mobile Applet for Weight Management in Obese Heart Failure Patients","The Impact of Dietary Management Applet for Weight Reduction in Obese Heart Failure Patients: a Multicenter, Single-blind Randomized Controlled Trial","IDEAL-HF","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Left ventricular ejection fraction (LVEF) ≤ 50%, with New York Heart Association (NYHA) class II-III;\n3. Body mass index (BMI) ≥ 26 kg\u002Fm² or male waist-to-hip ratio (WHR=waist circumference\u002Fhip circumference) ≥ 0.9, female waist-to-hip ratio ≥ 0.85;\n4. Ability to use a smartphone and demonstrate compliance via a diet management mobile application during a 2-week ±1-week run-in period;\n5. History of heart failure hospitalization within the past 6 months;\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. End-stage heart failure (≥2 hospitalizations for heart failure in the past 3 months, intolerance to guideline-directed medical therapy (GDMT), or dependence on inotropic agents);\n2. Heart failure with reversible causes (e.g., peripartum cardiomyopathy, fulminant myocarditis);\n3. Moderate or severe anemia (hemoglobin \\[Hb\\] \\\u003C90 g\u002FL);\n4. Renal insufficiency (estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 mL\u002Fmin\u002F1.73 m²) or ongoing dialysis;\n5. Uncontrolled thyroid disease (hyperthyroidism\u002Fhypothyroidism) or end-stage liver failure;\n6. Alcohol or substance abuse;\n7. Current use of weight-loss medications or planned bariatric surgery;\n8. Malignancy with an expected survival \\\u003C1 year;\n9. Conditions potentially hindering protocol compliance, as judged by the investigator (e.g., habitual reliance on food delivery services or company cafeteria meals);\n10. Planned hospitalization during the trial period;\n11. Concurrent participation in another interventional clinical study.",true,"18 Years",{"count":55,"type":19},830,[22],"The objective of this clinical trial is to investigate the effect of weight reduction through a diet management application and an intelligent weight scale on a composite cardiovascular endpoint in obese patients with heart failure.\n\nThe main questions are:\n\nDoes the use of a diet management APP and intelligent weight scale reduce 1-year all-cause mortality, heart failure hospitalization, and first heart failure hospital stay? Does the use of a diet management APP and intelligent weight scale improve the outcomes of assessment of heart failure frailty and quality of life for heart failure?\n\nResearchers will compare using the fully functional diet management app and intelligent weight scale to using the limitedly functional app and intelligent weight scale to see if the app works to improve heart failure conditions.\n\nParticipants will:\n\nUse the diet management app at every meal and the intelligent weight scale every day for 12 months, and visit the clinic at 12 months for checkups.",[59,60,61,62],"Heart Failure","Overweight and Obesity","Weight Loss","Heart Failure With Reduced Ejection Fraction","RECRUITING","2025-06-24",{"date":66,"type":35},"2025-06-27",{"date":68,"type":35},"2024-06-06",{"date":70,"type":19},"2026-12-31",{"name":41,"class":42},26,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":20,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100574818","effects-of-low-sodium-salt-on-death-hf-hospitalization-emergency-department-visits-and-quality-of-life-in-hf-patients-100574818","NCT06764225","Effects of Low-Sodium Salt on Death, HF Hospitalization\u002F Emergency Department Visits and Quality of Life in HF Patients","Effects of Low-Sodium Substitute Salt on Death, Heart Failure Hospitalization, Heart Failure Emergency Department Visits, and Quality of Life in Patients With Heart Failure: A Multicenter, Double-Blind, Randomized Controlled Trial","RESCUE-HF","Inclusion Criteria:\n\n1. Aged between 18 and 75 years;\n2. Hospitalized due to heart failure in the past year;\n3. NYHA functional class II-III;\n4. Echocardiographic evidence of LVEF \\\u003C 40% within the past 6 months;\n5. Receiving guideline-directed medical therapy for heart failure;\n6. Stable heart failure status, defined as heart failure stability for more than 4 weeks, with no increase in diuretic dose within the past 4 weeks;\n7. Having a primary caregiver and frequently dining together at home;\n8. Consuming commercially processed food no more than once a week;\n9. Providing written informed consent.\n\nExclusion Criteria:\n\n1. End-stage heart failure;\n2. Hospitalization due to cardiovascular causes within the past month;\n3. Uncorrected hyponatremia (Na \\\u003C 130 mmol\u002FL);\n4. Dialysis-dependent patients, or eGFR \\\u003C 20 mL\u002Fmin\u002F1.73m²;\n5. Uncontrolled hyperglycemia, with fasting blood glucose \\> 16 mmol\u002FL;\n6. Malignant cancer patients with a life expectancy of less than 1 year;\n7. Conditions that, in the investigator's opinion, may interfere with adherence to the protocol, such as habitual reliance on takeout meals or dining at company cafeterias;\n8. Planned hospitalization during the study period;\n9. Unexplained weight loss greater than 5 kg in the past year;\n10. The subject or family members have concerns about using the salt substitute in this study, or are planning for pregnancy, pregnant, or breastfeeding;\n11. Another family member is already participating in this study;\n12. The subject or family members are participating in other interventional clinical trials.","75 Years",{"count":83,"type":19},1301,[22],"This study aims to investigate whether using a low-sodium substitute salt can help improve outcomes for patients with heart failure. Specifically, it will examine if the low-sodium substitute salt can reduce death rates, hospital readmissions, and emergency visits, as well as improve the quality of life for these patients.",[59,87],"Dietary Sodium Intake",[89],"low-sodium substitute salt","2025-05-16",{"date":92,"type":35},"2025-05-21",{"date":94,"type":35},"2025-04-03",{"date":96,"type":19},"2027-04-30",{"name":41,"class":42},1,""]